1. Introduction {#sec1}
===============

Recurrent painful ophthalmoplegic neuropathy (RPON), previously known as ophthalmoplegic migraine (OM), is a rare condition (estimated annual incidence of 0,7 per million) involving headache and ophthalmoplegia, which typically occurs in children and young adults \[[@B1]\]. Typical features include repeated attacks of paralysis of one or more ocular cranial nerves (III, IV, or VI) with ipsilateral headache that can start up to two weeks before the onset of eye muscle weakness \[[@B2]\]. The International Classification of Headache Disorders 3rd edition-beta version (ICHD3*β*) defined the following diagnostic criteria for RPON: (1) at least two attacks; (2) unilateral headache accompanied by ipsilateral paresis of one, two, or three ocular motor nerves; (3) the exclusion of orbital, parasellar, or posterior fossa lesions by an appropriate investigation; and (4) the absence of another diagnosis that could better account for the patient\'s condition \[[@B3]\].

RPON was used to be classified as a migraine variant, but the disease concept has changed due to lack of migraine symptoms in many cases and evidence supporting neuropathy \[[@B1]\]. Brain MRI reveals gadolinium enhancement of the affected cranial nerve in approximately 75 % of patients suggesting that the condition is a demyelinating disorder \[[@B2]\]. However, the cause and classification remain controversial.

This lack of information about the disease pathophysiology makes the treatment even more controversial. In fact, there are very few data or consensus about RPON treatment. The aim of this study is to report a case where pregabalin was successfully employed after glucocorticoid therapy failure in RPON.

2. Case Report {#sec2}
==============

A 21-year-old female patient came to our service with a complaint of unilateral right-onset headache associated with diplopia initiated 6 months earlier. She had no personal or family remarkable antecedents. She never smoked. Six months earlier, the patient started to experience one-sided right throbbing headache. She denied nausea, vomiting, or photo- or phonophobia. Fifteen days after the pain onset, she noticed double vision and medial deviation of the right eye, which forced her to wear an eyepiece to perform her activities and drive. She went to several centers and used various medications such as paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and triptans without improvement. Three months earlier, she started using dexamethasone 4 mg daily with partial pain control but maintenance of diplopia.

At the examination, the patient had cushingoid face, violaceous striae, and right VI cranial nerve palsy with no other neurological changes. Blood tests were normal ([Table 1](#tab1){ref-type="table"}). A contrast-enhanced MRI scan of the brain did not show any remarkable features ([Figure 1](#fig1){ref-type="fig"}). A spinal tap released crystalline cerebrospinal fluid (CSF) with an opening pressure of 14 cm of water. Biochemical, microbiological, and cytological analyses of the CSF were normal ([Table 1](#tab1){ref-type="table"}). CT scan of thorax did not show any evidence of lymphoma or sarcoidosis.

Prednisone 1mg / kg was then started. With one week of treatment, complete reversal of ocular paralysis and remission of pain were observed. However, when the corticoid was gradually withdrawn, the patient returned to pain and returned to paralysis of the VI right pair. The prednisone was increased again to 1 mg / kg this time with reversion of ocular paralysis but without pain control. Several prophylaxis attempts were made with beta-blockers, calcium channel blockers, topiramate, and tricyclics without any symptomatic control that would allow corticosteroid withdrawal.

The pregabalin 150mg daily was then introduced. With 7 days of medication onset there was already an important remission of pain. With 15 days of pregabalin initiation, the retitration of prednisone was started without any intercurrence and the patient reversed the exogenous Cushing syndrome. Pregabalin was maintained for one year and retracted. Currently, the patient has been free of pain for 2 years.

3. Discussion {#sec3}
=============

According to the prevailing diagnostic criteria, our patients suffered from RPON given the presence of a documented VI nerve palsy associated with a unilateral ipsilateral headache with no remarkable alterations in laboratory or neuroimaging exams. Although the enhancement of the affected nerve occurs in 75% of patients \[[@B2]\], brain MRI is normal in a quarter of cases. We emphasize that our patient had been using a lower dose of corticosteroids for almost 3 months before admission, which may have reduced the sensitivity of the exam ([Figure 1](#fig1){ref-type="fig"}). Our patient responded partially to corticosteroids and absolutely to pregabalin but not to other treatment.

Since RPON is a very rare condition, it is difficult to conduct studies. There are no published treatment trials or guidelines for RPON and all evidence of effective treatments came from observational studies. Glucocorticoids seem to be beneficial for some patients. Prompt administration of steroids at the clinical onset may minimize permanent ophthalmoparesis or pupillary disfunction \[[@B4]\]. In a retrospective review of 80 patients, steroids were used to treat at least 31% of patients and there was a perceived benefit from corticosteroid treatment in 54 %. Only 12 % had no improvement or clinical worsening \[[@B2]\].

For those patients that do not respond to corticosteroids, treatment evidence is even smaller. The efficacy of drugs for migraine such as acetaminophen, NSAIDs, ergotamine, and triptans is unknown \[[@B1]\]. Pareja et al. described two cases of PRON responsive to indomethacin \[[@B5]\]. Also, cyproheptadine hydrochloride has been reported to prevent recurrent attacks of RPON by targeting the vascular edema around the oculomotor nerve \[[@B1]\].

Some authors recommend standard migraine prophylactic therapy for patients with recurrent attacks. We searched PubMed for case reports published between 2103 and 2017 using the search terms "ophthalmoplegic migraine" and "recurrent painful ophthalmoplegic neuropathy". We found 10 case reports that are displayed at [Table 2](#tab2){ref-type="table"}. After steroids, valproate and topiramate were the most prescribed medication. Both valproate and topiramate increase gamma-aminobutyric acid (GABA) levels in the brain and are first-line agents in migraine prevention ([Table 3](#tab3){ref-type="table"}) \[[@B6]\].

In more refractory cases, injection of botulinum toxin or strabismus surgery may be considered for patients with persistent sequelae, to correct eye misalignment \[[@B2]\].

As far as we know, pregabalin has not been reported for RPON treatment. Pregabalin is a structural analogue of GABA. Pregabalin binds to alpha 2-delta subunits of the voltage-gated calcium cannels in the nervous system, reducing the influx of calcium in the presynaptic ending, and, consequently, reduces the release of excitatory neurotransmitters including glutamate, noradrenaline, dopamine, and serotonin in the synaptic cleft \[[@B7]\]. Pregabalin has been used to treat neuropathic pain. The response to pregabalin and the lack of efficacy of classic drugs used in migraine, such as NSAIDs and first-line prophylactic migraine drugs (topiramate and valproate) in this case, reinforce the neuropathic etiology of the disease and not a variant of migraine as it was formerly classified.
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###### 

Results of blood and cerebrospinal fluid tests.

  --------------------- ----------
  Hemoglobin (g/dL)     13.1
                        
  WBC (/mm^3^)          12700
                        
  Platelets (/mm^3^)    298000
                        
  Na (mmol/L)           141
                        
  K (mmol/L)            4,1
                        
  Coagulation tests     Normal
                        
  Creatinine (mg/dL)    0,5
                        
  CPK (U/L)             38
                        
  ESR (mm/h)            22
                        
  Bilirubin (mg/dL)     0,27
                        
  AST (U/L)             16
                        
  ALT (U/L)             18
                        
  ALP(U/L)              64
                        
  GGT (U/L)             47
                        
  TSH (um/L)            0,8
                        
  ANA                   Negative
                        
  Anti-dsDNA            Negative
                        
  Anti-RNP              Negative
                        
  Anti-LA               Negative
                        
  Anti-RO               Negative
                        
  Anti-SM               Negative
                        
  ANCA                  Negative
                        
  HIV                   Negative
                        
  ACE (U/L)             31
                        
  VDRL test             Negative
                        
  Cerebrospinal fluid    
                        
   WBC (/mm^3^)         1
                        
   Protein (mg/dL)      22
                        
   Glucose (mg/dL)      66
                        
   Bacteria             Negative
  --------------------- ----------

WBC: white blood cells; Na: sodium; K: potassium; ESR: erythrocyte sedimentation rate; CPK: creatine phosphokinase; AST: aspartate aminotransferase; ALT: alanine transaminase; ALP: *alkaline phosphatase;  GGT:* gamma glutamyl transferase; TSH: thyroid stimulating hormone; ANA: antinuclear antibodies; Anti-dsDNA: anti-double stranded DNA antibodies; HIV: human immunodeficiency virus; ACE: angiotensin-converting enzyme; ANCA: anti-neutrophil cytoplasmic antibody; VDRL test: Venereal Disease Research Laboratory test.

###### 

Case reports.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                Patient age/ gender    Pain description          Nerve palsy           Treatment                       Time to fully recovery
  ------------------------------------- ---------------------- ------------------------- --------------------- ------------------------------- -------------------------------
  Kobayashi et al. 2017 \[[@B1]\]       48-year-old /female    Unilateral  \             Incomplete III pair   Corticosteroids                 5 days  \
                                                               Throbbing  \                                                                    Persistent Residual Mydriasis
                                                               Photophobia Phonophobia                                                         

                                                                                                                                               

  Qureshi et al. 2017 \[[@B8]\]         53-year-old / female   Unilateral  \             Incomplete III pair   NSAIDs  \                       NR
                                                               Throbbing  \                                    Serotonin receptor agonist  \   
                                                               Photophobia Phonophobia                         Calcium channel blocker         

                                                                                                                                               

  Huang et al. 2017 \[[@B9]\]           26-year-old / female   Unilateral                Incomplete III pair   Corticosteroids Topiramate      6 weeks

                                                                                                                                               

  Tripathi et al. 2017 \[[@B10]\]       36-year old / female   Unilateral  \             VI pair               Gabapentin  \                   2 months
                                                               Throbbing  \                                    Topiramate                      
                                                               Photophobia                                                                     

                                                                                                                                               

  Okura et al. 2017 \[[@B11]\]          12-year-old / male     Unilateral                Incomplete III pair   Corticosteroids                 8 weeks

                                                                                                                                               

  Takizawa et al. 2016 \[[@B12]\]       42-year-old / female   Unilateral  \             Incomplete III pair   NR                              NR
                                                               Throbbing                                                                       

                                                                                                                                               

  Ghosh 2015 \[[@B13]\]                 5-year-old / male      Unilateral                Incomplete III pair   Corticosteroids  \              3 weeks
                                                                                                               Immunoglobulin                  

                                                                                                                                               

  Ramakrishnan et al. 2015 \[[@B14]\]   30-year-old / female   Unilateral  \             Incomplete III pair   Valproate Corticosteroids       1 month
                                                               Photophobia Phonophobia                                                         

                                                                                                                                               

  Wang et al. 2014 \[[@B15]\]           63-year-old / male     Unilateral  \             Incomplete III pair   Valproate  \                    NR
                                                               Pressure-like\                                  Flunarizine                     
                                                               Phonophobia                                                                     

                                                                                                                                               

  Shetty et al. 2013 \[[@B16]\]         26-year-old / female   Unilateral  \             Incomplete III pair   NSAIDs Propranolol              2 weeks
                                                               Throbbing                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported; NSAIDs: nonsteroidal anti-inflammatory drugs.

###### 

Mechanisms of action of drugs used in headache.

  Drug              Mechanism of action
  ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Corticosteroids   inhibit the synthesis of inflammatory proteins, induce the expression of anti-inflammatory proteins and inhibit cyclooxygenase-2 \[[@B17]\]
                    
  Indomethacin      inhibition of cyclooxygenase 1 and cyclooxygenase 2 and phospholipase A2 \[[@B18]\]
                    
  Valproate         increases gamma-aminobutyric acid (GABA) levels in synaptosomes and in the brain, reduces the central trigeminal nerve activation (by increasing GABA levels), was shown to reduce experimental neurogenic inflammation in the peripheral trigeminal vascular system \[[@B6]\]
                    
  Topiramate        modifies the excitability of nerves by blocking voltage-sensitive sodium channels and L-type voltage-activated calcium channels, inhibits carbonic anhydrase activity, inhibits the excitatory glutamate pathway while enhancing the inhibitory effect of GABA \[[@B6]\]
                    
  Pregabalin        binds to alpha 2-delta subunits of the voltage-gated calcium cannels in the nervous system, reducing the influx of calcium in the presynaptic ending, and, consequently, reduces the release of excitatory neurotransmitters including glutamate, noradrenaline, dopamine, and serotonin in the synaptic cleft \[[@B7]\]
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